Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.

@article{Kraiem2012FrequencyOS,
  title={Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.},
  author={I. Kraiem and S. Hadhri and H. el Omri and R. Sassi and W. Chaabani and S. Ennabli and H. Skouri},
  journal={Annales de biologie clinique},
  year={2012},
  volume={70 6},
  pages={
          659-65
        }
}
  • I. Kraiem, S. Hadhri, +4 authors H. Skouri
  • Published 2012
  • Medicine
  • Annales de biologie clinique
    • Production of factor VIII or factor IX inhibitors is a major complication limiting the efficiency of substitutive therapy in haemophiliacs. Moreover, viral infections, the second serious complication of replacement therapy, may be associated to the occurrence of antiphospholipid antibodies which paradoxically lead to thrombosis. We investigated the prevalence of coagulation inhibitors (factor VIII and factor IX inhibitors, antiphospholipid antibodies) in Tunisian haemophiliacs, and we assessed… CONTINUE READING
    View PDF
    2 Citations
    2 Citations
    Citation Type

    Citation Type

    The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia
    • 5
    Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services

    References

    SHOWING 1-10 OF 39 REFERENCES
    Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients.
    • 30
    Lupus anticoagulant, anticardiolipin antibodies, and human immunodeficiency virus in haemophilia.
    • 34
    • PDF
    Antiphospholipid antibodies in haemophilia patients with severe bleeding tendency: cause, consequence or a consequential cause?
    • 4
    Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants.
    • 35
    • PDF
    Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    • 68
    Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.
    • 284
    • PDF
    Factor VIII haplotypes frequencies in Tunisian hemophiliacs A
    • 7
    The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C
    • 54
    Antiphospholipid antibodies, antiphospholipid syndrome and infections.
    • 152
    Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age
    • 167